TransMedics Group (NASDAQ:TMDX) Stock Lifted to “Hold” by Zacks Research

by · The Markets Daily

Zacks Research upgraded shares of TransMedics Group (NASDAQ:TMDX – Free Report) from a strong sell rating to a hold rating in a report issued on Monday morning,Zacks reports.

Other equities research analysts have also recently issued research reports about the stock. Weiss Ratings upgraded shares of TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. Needham & Company LLC reiterated a “buy” rating on shares of TransMedics Group in a research report on Friday, September 11th. Piper Sandler reissued an “overweight” rating and issued a $100.00 price objective (down from $120.00) on shares of TransMedics Group in a research note on Wednesday, August 5th. TD Cowen reissued a “buy” rating and issued a $120.00 price objective on shares of TransMedics Group in a research note on Tuesday, September 8th. Finally, Barclays began coverage on shares of TransMedics Group in a report on Wednesday, October 7th. They issued an “overweight” rating and a $120.00 target price on the stock. Five research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $115.60.

Get Our Latest Stock Report on TransMedics Group

TransMedics Group Trading Up 1.0%

Shares of TMDX stock opened at $67.34 on Monday. The company has a current ratio of 6.62, a quick ratio of 6.07 and a debt-to-equity ratio of 1.62. The stock has a market capitalization of $2.33 billion, a price-to-earnings ratio of 17.31, a price-to-earnings-growth ratio of 0.92 and a beta of 2.14. TransMedics Group has a 12-month low of $60.10 and a 12-month high of $156.00. The stock’s 50-day moving average price is $80.57 and its 200-day moving average price is $94.17.

TransMedics Group (NASDAQ:TMDX – Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The firm had revenue of $189.95 million for the quarter, compared to the consensus estimate of $184.00 million. During the same period in the previous year, the company posted $0.92 earnings per share. TransMedics Group’s quarterly revenue was up 20.7% on a year-over-year basis. Equities research analysts predict that TransMedics Group will post 1.46 EPS for the current fiscal year.

Insider Transactions at TransMedics Group

In other news, Director David Weill acquired 1,336 shares of the business’s stock in a transaction dated Friday, September 11th. The shares were purchased at an average price of $81.63 per share, with a total value of $109,057.68. Following the transaction, the director directly owned 16,392 shares in the company, valued at approximately $1,338,078.96. This represents a 8.87% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 6.90% of the company’s stock.

Institutional Trading of TransMedics Group

A number of institutional investors have recently bought and sold shares of TMDX. HB Wealth Management LLC lifted its position in TransMedics Group by 0.7% during the first quarter. HB Wealth Management LLC now owns 14,843 shares of the company’s stock valued at $1,476,000 after purchasing an additional 107 shares during the period. Pinnacle Wealth Planning Services Inc. boosted its holdings in TransMedics Group by 24.9% in the third quarter. Pinnacle Wealth Planning Services Inc. now owns 874 shares of the company’s stock valued at $73,000 after purchasing an additional 174 shares during the last quarter. Plan A Wealth LLC grew its position in TransMedics Group by 3.9% during the 3rd quarter. Plan A Wealth LLC now owns 5,370 shares of the company’s stock worth $448,000 after purchasing an additional 203 shares during the period. Whittier Trust Co. of Nevada Inc. grew its position in TransMedics Group by 95.0% during the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 425 shares of the company’s stock worth $45,000 after purchasing an additional 207 shares during the period. Finally, IFP Advisors Inc raised its stake in shares of TransMedics Group by 4.8% during the 2nd quarter. IFP Advisors Inc now owns 4,652 shares of the company’s stock valued at $309,000 after buying an additional 213 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Company Profile

(Get Free Report)

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation through systems that preserve and assess donor organs outside the body. The company’s primary platform is the Organ Care System (OCS), a portable, technology-enabled perfusion system designed to maintain organs in a functioning, near-physiologic state during transport and evaluation.

TransMedics offers OCS products for heart, lung and liver transplantation. Its systems are intended to support the use of organs that may not otherwise be suitable for conventional cold-storage methods, potentially expanding the donor pool and providing transplant teams with additional information when evaluating organs for transplantation.

Founded in 1998 and headquartered in Andover, Massachusetts, TransMedics serves transplant centers in the United States and select international markets.

Read More